Your browser doesn't support javascript.
loading
Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology.
Formica, María L; Awde Alfonso, Hamoudi G; Palma, Santiago D.
Afiliación
  • Formica ML; Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET and Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, Córdoba, 5000, Argentina.
  • Awde Alfonso HG; Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET and Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, Córdoba, 5000, Argentina.
  • Palma SD; Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA), CONICET and Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, Córdoba, 5000, Argentina.
Pharmacol Res Perspect ; 9(2): e00723, 2021 04.
Article en En | MEDLINE | ID: mdl-33694304
Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti-VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off-label used in the clinical practice. The schedule dosage involves repeated intravitreal injections of anti-VEGF agents to achieve and maintain effective concentrations in retina and choroids, which are administrated as solutions form. In this review article, we describe the features of different anti-VEGF agents, major challenges for their ocular delivery and the nanoparticles in development as delivery system of them. In this way, several polymeric and lipid nanoparticles are explored to load anti-VEGF agents with the aim of achieving sustained drug release and thus, minimize the number of intravitreal injections required. The main challenges were focused in the loading the molecules that maintain their bioactivity after their release from nanoparticulate system, followed the evaluation of them through studies of formulation stability, pharmacokinetic, and efficacy in in vitro and in vivo models. The analysis was based on the information published in peer-reviewed published papers relevant to anti-VEGF treatments and nanoparticles developed as ocular anti-VEGF delivery system.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Inhibidores de la Angiogénesis / Factor A de Crecimiento Endotelial Vascular / Sistema de Administración de Fármacos con Nanopartículas / Neovascularización Patológica Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Pharmacol Res Perspect Año: 2021 Tipo del documento: Article País de afiliación: Argentina Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos / Inhibidores de la Angiogénesis / Factor A de Crecimiento Endotelial Vascular / Sistema de Administración de Fármacos con Nanopartículas / Neovascularización Patológica Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Pharmacol Res Perspect Año: 2021 Tipo del documento: Article País de afiliación: Argentina Pais de publicación: Estados Unidos